Results 71 to 80 of about 11,915,644 (318)
“We Cannot Talk as a Family”: Complexities of Survivorship Communication Among Hispanic/Latino Young Adult Survivors of Childhood Cancer, Parents, and Clinicians
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background
Young adult childhood cancer survivors (YA‐CCS) have an increased risk of treatment‐related health complications throughout their lives. Lifelong survivorship care is recommended, yet many YA‐CCS experience disruptions in care during pediatric‐to‐adult transitions and do not receive recommended survivorship care.Kevin Shanchen Pu, Nicole Fernández‐Viña, Briana C. Martin‐Villa, Daniela Ramirez, Rebecca M. Lewinsohn, Mary Smith, Heidi Boynton, Lidia Schapira, Stephanie M. Smith +8 morewiley +1 more sourceIdentifying Patterns of Hospitalizations Among Childhood Cancer Survivors: A Population‐Based Study
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background
Childhood cancer survivors (CCSs) experience more hospitalizations than the general population. We aimed to identify distinct hospitalization patterns among Queensland CCSs and the associated characteristics. Methods
Cases (aged ≤14 years) diagnosed between 1995 and 2019 while residents of Queensland were identified through the ...Hai Pham, Teyl Engstrom, Peter Baade, Natalie Bradford, Sarah Pont, Louise Marquart‐Wilson, Natasha Nassar, Jason D. Pole +7 morewiley +1 more sourceClinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma
, 2022 Pancreatic cancer has a complex tumor microenvironment which engages in extensive crosstalk between cancer cells, cancer-associated fibroblasts, and immune cells. Many of these interactions contribute to tumor resistance to anti-cancer therapies.Christine Alewine, Samuel L. Ricci, Palestino Dominguez, Mayrel, Nebojsa Skorupan, Mayrel Palestino Dominguez, Alewine, Christine, Ricci, Samuel L., Skorupan, Nebojsa +7 morecore +1 more sourceSBRT embedded in low-dose RT plus αPD-1 (immuno-EclipseRT, iERT) elicits CD8+ T cell immunity against bulky tumors via an IFN-I/NK/DC axis
Nature CommunicationsBulky tumors remain challenging to treat, and immune checkpoint inhibitors (ICIs), alone or combined with conventional radiotherapy (RT), yield limited efficacy.Ren Luo, Min Yu, Kai Kang, Yufeng Zhang, Shanghai Liu, Zhuoran Yao, Zichong Peng, Xuanwei Zhang, Shuangsi Liao, Zhou Su, Linglu Yi, Hui Wang, Wenhao Zhao, Yue Zheng, Guo Lin, Ruizhan Tong, Feifei Na, Youling Gong, Meijuan Huang, Bingwen Zou, Long Bai, Renming Zhong, Di Yan, Gabriele Niedermann, Jianxin Xue, You Lu +25 moredoaj +1 more sourceEvidence‐Based Clinical Practice Guidelines for the Management of Pediatric Febrile Neutropenia: Resource‐Sensitive Recommendations for the Asian Continent
Pediatric Blood &Cancer, EarlyView.ABSTRACT
Febrile neutropenia (FN) is a frequent and serious complication in children receiving cancer therapy. Standardizing FN management across Asia is challenging due to variable healthcare infrastructure, diagnostic capacity, and infection patterns; however, it could improve resource use and patient outcomes.Joliza Patricia Cañeba, Shweta Bansal, Tea Reljic, Allyne Montecillo‐Aguelo, Hamidah Alias, Farrah Amaranto, Maria Stella Aquino‐Calingasan, Bambang Ardianto, Eggi Arguni, Sally Blair, Thi Tam Dang, Maria Beatriz Gepte, Samanmalee Gunasekara, Andini Handayani, Miriam Kimpo, Catherine G. Lam, Nawachai Lertvivatpong, Sergio Licona, Ana Loseo, Ratha Mlis, Vivian Moreno Berrio, Nguyen Hoai Anh, Anna Lisa Ong‐Lim, Ha Thu Pham, Krishna Sagar Sharma, Bun Sereyleak, Sally Jane G. Velasco‐Aro, Su Yadana, Ambuj Kumar, Sheena Mukkada +29 morewiley +1 more sourceCXCR4-modification enhances CAR-T efficacy by improving tumor tracking and bone marrow homing in B-cell malignancies
Signal Transduction and Targeted TherapyHematological malignancies of B cell origin are characterized by frequent expression of CXCR4. The CXCR4-CXCL12 axis facilitates the in vivo dissemination of B cell lymphoma and multiple myeloma (MM).Pei Shu, Fuchun Guo, Diyuan Qin, Liqun Zou, Qizhi Ma, Benxia Zhang, Ge Gao, Yue Chen, Xia He, Ming Jiang, Ning Liu, Kexun Zhou, Jian Zhao, Yanna Lei, Yu Gao, Yugu Zhang, Yao Zeng, Mingyang Feng, Xiaoyu Li, Dan Li, Yongsheng Wang +20 moredoaj +1 more sourceCombining immune checkpoint inhibitors with thoracic radiotherapy enhances outcomes in advanced non-small-cell lung cancer: a real-world study
Frontiers in OncologyBackgroundWe aimed to evaluate the efficacy of thoracic radiotherapy (TRT) combined with immune checkpoint inhibitors (ICIs) in patients with advanced non-small-cell lung cancer (NSCLC) in real-world clinical settings and identify predictive subgroups ...Yao Zou, Yao Zou, Yao Zou, Yichong Chen, Xiaojuan Zhou, Youling Gong, Yong Xu, Bingwen Zou, Feng Peng, Meijuan Huang, You Lu, Yongmei Liu +11 moredoaj +1 more sourceBone and Soft Tissue Neoplasms in Infants Versus Older Children: A Report From the Cancer in Young People in Canada Program
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background and Aims
Infant bone and soft tissue neoplasms present distinct clinical challenges and lack large‐scale data to inform treatment decisions. This study aims to characterize bone and soft tissue neoplasms in infants in Canada and to compare their outcomes with those of older pediatric patients.Samuel Sassine, Hallie Coltin, Maria Kondyli, Monia Marzouki, Nicolas Prud'homme, Nida Usmani, Rebecca J. Deyell, Lesleigh Abbott, Tony H. Truong, Sapna Oberoi, Ketan Kulkarni, Josée Brossard, Lynette Bowes, Paul Gibson, Sarah McKillop, Roona Sinha, Lillian Sung, Catherine Vezina, Laura Wheaton, Alexandra P. Zorzi, Marie‐Claude Pelland‐Marcotte, Thai Hoa Tran +21 morewiley +1 more sourceImpact of Initial Treatment Setting on Survival in Relapsed Pediatric and AYA Bone Sarcomas: A Secondary Analysis of a Prospective Clinical Trial
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background
Outcomes in relapsed or refractory pediatric and AYA bone sarcomas remain poor, and the impact of early referral to specialized sarcoma centers on survival is unclear. Early centralization of care may improve local and systemic treatment quality, but evidence in this population is limited.Justyna Antoniuk‐Majchrzak, Katarzyna Bilska, Tomasz Koziński, Jadwiga Węcławek‐Tompol, Dorota Sega‐Pondel, Radosław Chaber, Wanda Badowska, Katarzyna Rosłan, Hanna Koseła‐Paterczyk, Anna Raciborska +9 morewiley +1 more sourceThe price of tumor control [PDF]
, 2013 Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% of patients.Berking, Carola, Bockmeyer, Clemens L., Voskens, Caroline J., Fluck, Michael, Heinzerling, Lucie M., Schuler, Gerold, Vaubel, Julia, Keller, Ullrich, Goldinger, Simone M., Wilhelm, Tabea, Moos, Roger von, Mohr, Peter, Eigentler, Thomas, Paetzold, Sylvie, Justich, Armin, Hundorfean, Gheorghe, Hauschild, Axel, Mateus, Christine, Klein, Christina, Loquai, Carmen, Schadendorf, Dirk, Göppner, Daniela, Robert, Caroline, Bergmann, Tanja, Gutzmer, Ralf, Hein, Rüdiger, Grabbe, Stephan, Dummer, Reinhard, Kaehler, Katharina C., Trefzer, Uwe, Ulrich, Jens, Weder, Patrik, Schuler-Thurner, Beatrice, Garbe, Claus, Satzger, Imke, Schlaeppi, Marc +35 morecore +1 more source